as of 10-01-2026 3:44pm EST
Damora Therapeutics Inc is a biotechnology company that aims to fundamentally redefine care for people with hematologic disorders. The group is advancing a new generation of biologics to treat mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis, where there is cruicial medical need for disease-modifying treatments. Its goal is to rapidly bring forward optimized therapies with broad mutation coverage and exceptional convenience to dramatically improve patient outcomes. The group's pipeline products are DMR-001, DMR-002, DMR-003, and GB3226.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 1.5B | IPO Year: | 2020 |
| Target Price: | $46.89 | AVG Volume (30 days): | 607.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | quarterly |
| EPS: | -0.79 | EPS Growth: | 121.48 |
| 52 Week Low/High: | $16.50 - $34.89 | Next Earning Date: | 11-05-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -26.30 | Index: | N/A |
| Free Cash Flow: | -6922000.0 | FCF Growth: | N/A |
Director, President and CEO
Avg Cost/Share
$20.23
Shares
12,500
Total Value
$252,875.00
Owned After
512,500
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Jarrett Jennifer | DMRA | Director, President and CEO | Sep 25, 2026 | Buy | $20.23 | 12,500 | $252,875.00 | 512,500 |
See how DMRA stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "DMRA Damora Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.